Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Truxima Rituximab Cancelled
Tudorza Genuair Aclidinium bromide Chronic Obstructive Pulmonary Disease List with criteria/condition Complete
Tukysa tucatinib Advanced or Metastatic Breast Cancer Reimburse with clinical criteria and/or conditions Complete
Twynsta Telmisartan / Amlodipine Hypertension Cancelled
Twynsta Telmisartan/ Amlodipine Hypertension List Complete
Tykerb (in combination with Letrozole) Lapatinib Metastatic Breast Cancer Do not reimburse Complete
Tysabri natalizumab Multiple Sclerosis, relapsing-remitting Withdrawn
Tysabri Natalizumab Multiple Sclerosis, relapsing-remitting Do not list Complete
Tysabri Natalizumab Multiple Sclerosis, relapsing-remitting List with clinical criteria and/or conditions Complete
Uloric Febuxostat Gout List with clinical criteria and/or conditions Complete